The introduction of the first antipsychotic medication in the early 1950s revolutionized mental
health care strategies and led to the era of deinstitutionalization, a period in which patients …

Experimental therapeutic research for schizophrenia is rapidly expanding and a number of
compounds with novel mechanisms of action are demonstrating encouraging evidence for …

Numerous attempts to extend the pharmacotherapy of schizophrenia beyond conventional
neuroleptics are reviewed. Clozapine and melperone are atypical neuroleptics that produce …

The clinical management of schizophrenia is hampered by a variety of important limitations
of available antipsychotic agents. Current evidence suggests that among recently relapsed …

The currently available antipsychotics mostly treat the positive symptoms of schizophrenia
and have at least one adverse effect as a potential liability. Encouraging data suggest …

Traditionally, schizophrenia was considered to be a severe psychiatric disorder, with a
chronic course and an unfavorable outcome. Throughout history, there has been incidence …

Schizophrenia is an illness that has been recognized for millennia; despite this, the
discovery of antipsychotic medications for its treatment has occurred only in the past half …

Antipsychotics remain the current standard of care for mental disorders including
schizophrenia (~ 1% prevalence) and bipolar mania (~ 3% prevalence), and generate over …

Antipsychotic drugs for the treatment of schizophrenia arrived in the clinic in the fifties of the
previous century and have since been the most effective treatment for patients with this …

The pharmacological choices for the treatment of schizophrenia have been greatly
expanded with the availability of the atypical compounds clozapine (Clozaril®, Novartis) …